Symptomatic Therapy for Patients With Huntington's Disease

Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04071639

Enrollment

Registered

2019-08-28

Start date

2020-03-12

Completion date

2024-12-31

Last updated

2021-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington Disease

Brief summary

Based on the previous symptomatic treatment of Chinese HD patients, this study intends to further optimize the treatment regimen of Chinese HD patients so as to further improve the prognosis of patients.

Detailed description

The purpose of the study is to evaluate symptomatic treatment regimen efficacy based on different disease stages. We previously used symptomatic treatment on Chinese HD patients and most of them got improved both in the motor symptoms and life quality. So this study intends to further optimize the treatment regimen, and set a control group to further evaluate the treatment efficacy.

Interventions

DRUGHaloperidol 2Mg Tab

Haloperidol take 0.5mg\ 2mg three time a day.

DRUGRisperidone 1Mg Tab

Risperidone take 1mg once at night.

DRUGZoloft 50Mg Tablet

Zoloft take 50mg once in the morning.

DRUGIdebenone

Idebebone take 30mg three times a day.

DRUGDeutetrabenazine Oral Tablet [Austedo]

The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Case group use Deutetrabenazine，Risperidone，Zoloft and Idebenone(depending on demand and symptom). Control group use Haloperidol，Risperidone，Zoloft and Idebenone(depending on demand and symptom).

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Genetic diagnosis of Huntington's disease 2. Symptomatic patients with Huntington's disease 3. Disease duration less than 5 years -

Exclusion criteria

(1) Movement disorder due to other definite causes instead of Huntington's disease (2) Severe Lung, kidney or liver disease (3) Neoplastic Disease \-

Design outcomes

Primary

Measure	Time frame	Description
The Unified Huntington's Disease Rating Scale	Five years	The Unified Huntington's Disease Rating Scale consist of four subscales, including motor(0-124), MMSE (0-30), psychiatric (0-176), and functional domains(1-13). Four subscale scores are summed to compute a total score. Higher motor and psychiatric scores represent worse outcomes but higher MMSE score and functional scores indicate good outcome.

Secondary

Measure	Time frame	Description
Brain MRI	Five years	Brain MRI is used to assess the atrophy of caudate nucleus and cortex in HD patients

Countries

China

Contacts

Primary ContactZhi-Ying Wu, MD

zhiyingwu@zju.edu.cn0086-571-87783569

Backup ContactXiao-Yan Li

827011044@qq.com0086-17816872805

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026